Group 1 - GSK and Amgen will add their medicines to TrumpRX, a prescription drug website initiated by the Trump administration [1] - The collaboration aims to enhance the availability of medications through the platform [1]

Core Viewpoint - The White House is set to announce an expansion of drugmakers offering discounts on TrumpRx.gov, with Amgen and GSK being added to the list, totaling 54 medications from six companies under most-favored-nation pricing [1][6]. Group 1: Drug Pricing and Discounts - Amgen will offer discounts of up to 80% on its medication Amjevita, reducing the price from $1,484 to $299, which treats rheumatoid arthritis, psoriasis, and ulcerative colitis [2]. - GSK plans to offer discounts of 62% on Aimovig and Repatha, and 55% on Incruse, which will be priced at $159 for COPD treatment. Other GSK drugs will have discounts ranging from 10% to 51% [5]. Group 2: Government Policy and Industry Response - The initiative is part of President Trump's push for affordable healthcare, with expectations of greater discounts and transparency in drug pricing as Congress considers the Great Healthcare Plan [7]. - The Pharmaceutical Research and Manufacturers of America has expressed concerns that government-imposed pricing policies could undermine U.S. competitiveness and negatively impact research and development funding [9][10]. Group 3: Historical Context of Drug Pricing - Under the Biden administration, prescription drug costs have increased by 10.4% from January 2021 to January 2025, while under the Trump administration, prices rose only 0.2% from January 2025 to February 2026 [13].

Core Insights - Mineralys Therapeutics, Inc. is focused on developing innovative therapies for cardiovascular and renal diseases, addressing unmet medical needs through advanced research and development efforts [1] - The company is competing within the pharmaceutical sector, aiming to bring effective treatments to market and challenge other companies in the same space [1] Financial Performance - On March 13, 2026, a price target of $30 was set for MLYS by Dennis Ding from Jefferies, indicating a potential upside of approximately 14.37% from the trading price of $26.23 at that time [2] - MLYS's Q4 2025 earnings call provided insights into its financial performance and strategic initiatives, highlighting significant developments and plans for growth [3] - Currently, MLYS is priced at $26.19, reflecting a decrease of 2.96% with a drop of $0.80, and has fluctuated between a low of $25.45 and a high of $28.65 during the day [4] - Over the past year, MLYS has experienced significant volatility, reaching a high of $47.65 and a low of $10.44 [4][6] - The company's market capitalization is approximately $1.74 billion, indicating its size and market presence [5] - Today's trading volume for MLYS on NASDAQ is 1,380,806 shares, reflecting active investor interest and engagement [5]

Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team ...

Core Viewpoint - Pfizer Inc. (PFE) is currently undervalued, trading at 8-9 times forward earnings, but there are strong indicators suggesting a potential comeback for the company [1]. Group 1 - The trading price of Pfizer is around $25, indicating a low valuation compared to its earnings potential [1]. - The insights are supported by Alfred Marcus, a professor at the University of Minnesota, who has authored multiple books on strategy and management [1]. - The article emphasizes the possibility of great companies, like Pfizer, rising again despite current market perceptions [1].

Core Viewpoint - The Ontario and Manitoba Health Coalitions are calling for a judicial inquest into the operations of Grifols following reports of patient deaths and non-compliance issues at their plasma harvesting centers [1][2][3] Group 1: Patient Safety and Compliance Issues - Two patients died in Winnipeg after having their blood plasma harvested at Grifols centers, raising serious safety concerns [1] - Grifols has been found non-compliant with serious breaches at multiple centers, including Calgary, St. John, Regina, and Saskatoon [1] - Inspection reports from Health Canada indicate repeated failures at Grifols' facilities, prompting calls for accountability [3][4] Group 2: Legislative and Ethical Concerns - The Ontario Health Coalition is advocating for the end of Grifols' contract with Canadian Blood Services (CBS) and the expansion of the voluntary public donation system [2][4] - The Voluntary Blood Donations Act prohibits paid plasma harvesting, yet CBS signed a 15-year contract with Grifols in 2022, which contradicts the intent of the legislation [4] - Advocacy groups emphasize that for-profit companies should not be allowed to harvest human blood, citing moral and ethical implications [3][6] Group 3: Economic and Social Implications - Grifols has been advertising potential earnings of $6,890 per year for plasma donations, which may attract low-income individuals to sell their plasma out of financial desperation [6][7] - The practice of frequent plasma harvesting raises concerns about health impacts, particularly for economically disadvantaged individuals [5][8] - Comparisons are drawn between the U.S. and Canada regarding plasma harvesting frequency, with calls for a more cautious approach in Canada [8]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Vistagen Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on March 16, 2026 [1]. Group 1: Class Action Details - Investors who bought Vistagen common stock between April 1, 2024, and December 16, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 16, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Background - The lawsuit alleges that Vistagen's defendants provided misleading information regarding the development and commercialization of its drug fasedienol, which is intended for treating social anxiety disorder [5]. - Defendants reportedly made positive assertions about fasedienol's trial success while concealing material adverse facts about the Phase 3 PALISADE-3 trial, leading to investor damages when the truth was revealed [6].

Core Insights - The article emphasizes the value of in-depth analysis in the Biotech sector, highlighting the services offered by Biotech Analysis Central, which includes a library of over 600 articles and a model portfolio of small and mid-cap stocks [2] Group 1 - The Biotech Analysis Central service is available for $49 per month, with a discounted annual plan at $399, representing a 33.50% savings for subscribers [1] - The service aims to assist healthcare investors in making informed decisions through comprehensive analysis and news reports [2] - The author has a background in Applied Science, which is leveraged to generate long-term value in the healthcare sector [2]

NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 4, 2026. SO WHAT: If you purchased Aquestive securities during the Class Peri ...

Core Viewpoint - Novartis' Cosentyx (secukinumab) has received FDA approval for treating pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa (HS), marking it as the only IL-17A inhibitor available for this demographic [1][6]. Group 1: Product Approval and Significance - The approval of Cosentyx provides a distinct biologic treatment option for pediatric patients with HS, allowing for tailored treatment approaches [1][4]. - This marks the fourth pediatric indication for Cosentyx, reinforcing its established safety and efficacy profile [6]. Group 2: Impact on Patients and Healthcare - HS often begins in adolescence and can lead to irreversible scarring and disabilities, highlighting the need for early intervention [2][7]. - The approval is seen as a significant advancement for younger patients who have had limited treatment options, bringing hope for improved management of the condition [3][4]. Group 3: Mechanism and Dosing - Cosentyx operates through a differentiated IL-17A mechanism, providing physicians with a new therapeutic option for managing HS in younger patients [3][6]. - The dosing for patients aged 12 and older weighing 30 kg or more is supported by adult studies and pharmacokinetic modeling, ensuring similar exposure levels to adult HS patients [3][5]. Group 4: Company Background - Novartis has over a decade of real-world experience with Cosentyx across multiple autoimmune diseases, establishing it as a trusted treatment option among physicians [4][5]. - Since its launch in 2015, Cosentyx has treated over 1.8 million patients globally and is approved in more than 100 countries [5].